Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Seminars in Hematology

Volumn 46, Issue 2, 2009, Pages 158-165

  Bruno, Benedetto ^a   Giaccone, Luisa ^a   Sorasio, Roberto ^a   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD52 ANTIGEN; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HUMAN; IRRADIATION; MORTALITY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; T CELL DEPLETION;

FEMALE; GRAFT VS TUMOR EFFECT; HUMANS; MALE; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 64749108665     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.02.001     Document Type: Article

References (66)

1. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
2. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
3. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
4. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., and Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7 (2007) 585-598
5. Bruno B., Giaccone L., Rotta M., Anderson K., and Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19 (2005) 1729-1738
6. Barlogie B., Tricot G.J., van Rhee F., Angtuaco E., Walker R., Epstein J., et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135 (2006) 158-164
7. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
8. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al., Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
9. Attal M., Harousseau J.L., Facon T., Guilhot F., Doyen C., Fuzibet J.G., et al., InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
10. Cavo M., Tosi P., Zamagni E., Cellini C., Tacchetti P., Patriarca F., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 25 (2007) 2434-2441
11. Mehta J., and Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 22 (1998) 835-843
12. Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325 (1991) 1267-1273
13. Bensinger W.I., Buckner C.D., Anasetti C., Clift R., Storb R., Barnett T., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
14. Gahrton G., Tura S., Ljungman P., Bladé J., Brandt L., Cavo M., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13 (1995) 1312-1322
15. Bensinger W.I. Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12 (2007) 4384-4392
16. Kröger N., Schwerdtfeger R., Kiehl M., Sayer H.G., Renges H., Zabelina T., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
17. Maloney D.G., Molina A.J., Sahebi F., Stockerl-Goldstein K.E., Sandmaier B.M., Bensinger W., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
18. Kwak L.W., Taub D.D., Duffey P.L., Bensinger W.I., Bryant E.M., Reynolds C.W., et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345 (1995) 1016-1020
19. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., and Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 87 (1996) 1196-1198
20. Verdonck L.F., Lokhorst H.M., Dekker A.W., Nieuwenhuis H.K., and Petersen E.J. Graft-versus-myeloma effect in two cases. Lancet 347 (1996) 800-801
21. Zeiser R., Bertz H., Spyridonidis A., Houet L., and Finke J. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 34 (2004) 923-928
22. Lokhorst H.M., Schattenberg A., Cornelissen J.J., Thomas L.L., and Verdonck L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90 (1997) 4206-4211
23. Lokhorst H.M., Schattenberg A., Cornelissen J.J., van Oers M.H., Fibbe W., Russell I., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18 (2000) 3031-3037
24. Lokhorst H.M., Wu K., Verdonck L.F., Laterveer L.L., van de Donk N.W., van Oers M.H., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103 (2004) 4362-4364
25. van de Donk N.W., Kröger N., Hegenbart U., Corradini P., San Miguel J.F., Goldschmidt H., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 37 (2006) 1135-1141
26. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, et al. Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood. In press.
27. Corradini P., Voena C., Tarella C., Astolfi M., Ladetto M., Palumbo A., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 17 (1999) 208-215
28. Bensinger W.I., Maloney D., and Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 38 (2001) 243-249
29. Reece D.E., Shepherd J.D., Klingemann H.G., Sutherland H.J., Nantel S.H., Barnett M.J., et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 15 (1995) 117-123
30. Barlogie B., Kyle R.A., Anderson K.C., Greipp P.R., Lazarus H.M., Hurd D.D., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
31. Gahrton G., Svensson H., Cavo M., Apperly J., Bacigalupo A., Björkstrand B., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113 (2001) 209-216
32. Storb R., Yu C., Wagner J.L., Deeg H.J., Nash R.A., Kiem H.P., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
33. McSweeney P.A., Niederwieser D., Shizuru J.A., Sandmaier B.M., Molina A.J., Maloney D.G., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
34. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood. In press.
35. Mohty M., Boiron J.M., Damaj G., Michallet A.S., Bay J.O., Faucher C., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 77-84
36. Peggs K.S., Mackinnon S., Williams C.D., D'Sa S., Thuraisundaram D., Kyriakou C., et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 9 (2003) 257-265
37. Einsele H., Schäfer H.J., Hebart H., Bader P., Meisner C., Plasswilm L., et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 121 (2003) 411-418
38. Giralt S., Aleman A., Anagnostopoulos A., Weber D., Khouri I., Anderlini P., et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 30 (2002) 367-373
39. Gerull S., Goerner M., Benner A., Hegenbart U., Klein U., Schaefer H., et al. Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 36 (2005) 963-969
40. Bruno B., Sorasio R., Patriarca F., Montefusco V., Guidi S., Busca A., et al. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Eur J Haematol 78 (2007) 330-337
41. Lee C.K., Badros A., Barlogie B., Morris C., Zangari M., Fassas A., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 31 (2003) 73-80
42. Kröger N., Sayer H.G., Schwerdtfeger R., Kiehl M., Nagler A., Renges H., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 100 (2002) 3919-3924
43. Crawley C., Iacobelli S., Björkstrand B., Apperley J.F., Niederwieser D., and Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109 (2007) 3588-3594
44. Bruno B., Rotta M., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. A comparison of allografting with autografting for newly-diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
45. Bruno B., Sorasio R., Patriarca F., Mordini N., Allione B., Carnevale-Schianca F., et al. An update of a comparison of nonmyeloablative allografting with autografting for newly diagnosed multiple myeloma. Presented at the 35th Annual Meeting of the European Group for Bone Marrow Transplantation; Goteborg, Sweden; March 29-April 1 (2009)
46. Garban F., Attal M., Michallet M., Hulin C., Bourhis J.H., Yakoub-Agha I., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
47. Moreau P., Garban F., Attal M., Michallet M., Marit G., Hulin C., et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. Blood 112 (2008) 3914-3915
48. Desikan R., Barlogie B., Sawyer J., Ayers D., Tricot G., Badros A., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95 (2000) 4008-4010
49. Shaughnessy Jr. J., Tian E., Sawyer J., McCoy J., Tricot G., Jacobson J., et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 120 (2003) 44-52
50. Barlogie Jr. B., and Shaughnessy J.D. Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol 76 Suppl 1 (2002) 337-339
51. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109 (2007) 3489-3495
52. Schilling G., Hansen T., Shimoni A., Zabelina T., Pérez-Simón J.A., Gutierrez N.C., et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 22 (2008) 1250-1255
53. Rosiñol L., Pérez-Simón J.A., Sureda A., de la Rubia J., de Arriba F., Lahuerta J.J., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 (2008) 3591-3593
54. Lowsky R., Takahashi T., Liu Y.P., Dejbakhsh-Jones S., Grumet F.C., Shizuru J.A., et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 353 (2005) 1321-1331
55. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
56. Alyea E., Weller E., Schlossman R., Canning C., Webb I., Doss D., et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 98 (2001) 934-939
57. Hale G., Jacobs P., Wood L., Fibbe W.E., Barge R., Novitzky N., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 26 (2000) 69-76
58. Lokhorst H.M., Segeren C.M., Verdonck L.F., van der Holt B., Raymakers R., van Oers M.H., et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 21 (2003) 1728-1733
59. Harousseau J.L. The allogeneic dilemma. Bone Marrow Transplant 40 (2007) 1123-1128
60. Bruno B., Patriarca F., Sorasio R., Mattei D., Montefusco V., Peccatori J., et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 91 (2006) 837-839
61. van de Donk N.W., Kröger N., Hegenbart U., Corradini P., San Miguel J.F., Goldschmidt H., et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood 107 (2006) 3415-3416
62. Kröger N., Shimoni A., Zagrivnaja M., Ayuk F., Lioznov M., Schieder H., et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 104 (2004) 3361-3363
63. Kröger N., Zabelina T., Ayuk F., Atanackovic D., Schieder H., Renges H., et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 34 (2006) 770-775
64. Shaughnessy Jr. J.D., Zhan F., Burington B.E., Huang Y., Colla S., Hanamura I., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109 (2007) 2276-2284
65. Shaughnessy Jr. J.D., Haessler J., van Rhee F., Anaissie E., Pineda-Roman M., Cottler-Fox M., et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol 137 (2007) 530-536
66. Matsui S., Yamanaka T., Barlogie B., Shaughnessy Jr. J.D., and Crowley J. Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Stat Med 27 (2008) 1106-1120